The Liquidity Crisis in Clinical Evidence: How Funding Shocks and Neurotrauma Data Are Reshaping Medical Research
The U.S. medical research landscape faces structural vulnerabilities, highlighted by NIH grant terminations disrupting 7...
Read More →Breakthroughs in medical science and clinical trials.
The U.S. medical research landscape faces structural vulnerabilities, highlighted by NIH grant terminations disrupting 7...
Read More →The convergence of AI-driven drug discovery and decentralized clinical trials is fundamentally restructuring medical res...
Read More →The medical research sector faces a critical bifurcation in 2026, with breakthrough FDA approvals and CRISPR milestones ...
Read More →Three regenerative medicine breakthroughs—pediatric CRISPR expansion, cartilage regeneration via 15-PGDH inhibition, a...
Read More →Novo Nordisk's Phase 3 EVOKE trial failure for oral semaglutide in Alzheimer's disease has shattered the biotech industr...
Read More →The August 2026 convergence of accelerated FDA approvals and AI-driven clinical trial optimization marks a structural pi...
Read More →The FDA's August 2026 approvals of oncolytic viruses and CELMoD therapies fundamentally reset the biopharma oncology lan...
Read More →Eli Lilly filed six lawsuits, five in Texas, against sellers of unapproved retatrutride, a triple-agonist obesity drug t...
Read More →The CDC's August 13 tally of 2,566 confirmed U.S. measles cases in 2026 surpasses last year's total and marks a 35-year ...
Read More →UCLA's MethylScan, published in PNAS, reads cell-free DNA methylation to detect multiple cancers and liver disease from ...
Read More →